Claims for Patent: 9,937,183

Summary for Patent: 9,937,183

Title:	Antimicrobial compounds and methods of making and using the same
Abstract:	Methods and compounds for treating, preventing, reducing the risk of and/or delaying the onset of a microbial infection in a subject are disclosed herein, wherein the microbial infection is caused by one or more microorganisms (e.g., one or more bacteria) which can be used as a biological weapon, such as Bacillus anthracis, Franciscella tularensis, Yersinia pestis, Burkholderia mallei, and Burkholderia pseudomallei. Also disclosed are pharmaceutical compositions or kits for treating, preventing, reducing the risk of and/or delaying the onset of a microbial infection.
Inventor(s):	Kanyo; Zoltan F. (New Haven, CT), Bhattacharjee; Ashoke (New Haven, CT)
Assignee:	Melinta Therapeutics, Inc. (New Haven, CT)
Application Number:	14/917,920
Patent Claims:	1. A method of treating a microbial infection in a subject, comprising administering to the subject an effective amount of a compound selected from Compounds 1-17: ##STR00021## ##STR00022## ##STR00023## ##STR00024## and stereoisomers, tautomers, and salts thereof, wherein the infection is caused by or involves one or more microorganisms which are capable of being used as biological weapons, or the infection is caused by or involves one or more microorganisms which are extremely-drug resistant Gram-positive or Gram-negative pathogens. 2. The method of claim 1, wherein the compound is selected from the group consisting of Compounds 14-17, stereoisomers, tautomers, and salts thereof. 3. The method of claim 1, wherein the one or more microorganisms are selected from the group consisting of biodefense category A pathogens Bacillus anthracis (anthrax), Yersinia pestis (plague), and Fracisella tularensis (tularemia). 4. The method of claim 1, wherein the one or more microorganisms are selected from the group consisting of biodefense category B pathogens Burkholderia pseudomallei, Coxiella burnetii (Q fever), Brucella species (brucellosis), Burkhoderia mallei (glanders), Chlamydia psittaci (Psittacosis), Typhus fever (Rickettsia prow azekii), Diarrheagenic E. coli, Pathogenic Vibrios, Shigella species, Salmonella, Listeria monocytogenes, Campylobacter jejuni, and Yersinia enterocolitica. 5. The method of claim 1, wherein the one or more microorganisms are selected from Bacillus anthracis, Franciscella tularensis, Yersinia pestis, Burkholderia mallei, and Burkholderia pseudomallei. 6. The method of claim 5, wherein the one or more microorganisms are Burkholderia pseudomallei. 7. The method of claim 1, wherein the one or more microorganisms are extremely-drug resistant Gram-positive or Gram-negative pathogens. 8. The method of claim 1, wherein the compound is selected from the group consisting of Compounds 1-13, stereoisomers, tautomers, and salts thereof, and the one or more microorganisms are selected from Burkholderia mallei and Burkholderia pseudomallei. 9. The method of claim 1, wherein the salts are pharmaceutically acceptable salts. 10. The method of claim 1, wherein the effective amount is from about 0.1 mg to about 1500 mg, wherein about means within 15% more or less of the specified value. 11. The method of claim 1, wherein the compound is administered otically, ophthalmically, nasally, orally, parenterally, topically, or intravenously.

Details for Patent 9,937,183

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2033-09-09